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We describe the clinical, gross and microscopic features of undiﬀerentiated uterine stromal sarcoma associated with osteoclast-
like giant cells. A case of low-grade endometrial stromal sarcoma is already described in association with osteoclast-like giant
cells; however, the current case diﬀers in that the tumor was a high grade and did not show any evidence of smooth muscle
or epithelioid diﬀerentiation and was shown to be strongly positive for CD10 and focally for WT-1 and Inhibin supporting an
endometrial stromal origin. The associated osteoclast-like giant cells were abundant, evenly distributed within the tumor and
showed strong positivity for CD68. Interestingly, rare (less than 2%) giant cells also showed weak cytoplasmic positivity for
b-hCG. The tumorinﬁltrated deep into the myometrium and had marked lymphovascularinvasion.Althoughthe regionallymph
nodes and peritoneal washings were negative, the lesion showed a highly aggressive clinical course. Despite treatment, the tumor
disseminated within the abdominalcavity and lungs and ultimately led to the patient’s demise within 9 months of the diagnosis.
1.Introduction
Endometrial stromal sarcomas are rare tumors comprising
approximately 1-2% of all tumors of the uterine corpus.
Larson etal.[1]showed thatthemeanageofpresentationfor
low-grade endometrial stromal sarcoma was approximately
47.2 years and for high-grade endometrial sarcoma about
50 years with a most common presenting symptom of
menorrhagia. Classically, the distinction between low-grade
and high-grade endometrial stromal sarcoma was based
on mitotic count; however, since high-grade endometrial
stromal sarcoma bears no histologic resemblance to low-
grade endometrial stromal sarcoma, it has been proposed
that high-grade tumors be renamed to undiﬀerentiated
endometrial sarcoma. WHO deﬁnes this sarcoma as: “High-
grade endometrial stromal sarcoma that lacks speciﬁc diﬀer-
entiationandbearsnohistologicresemblancetoendometrial
stroma” [2]. This undiﬀerentiated tumor presents with
increased mitotic count, more than 10 mitoses/10HPF and
show an aggressive clinical course. Death occurs from tumor
dissemination within 3 years after the diagnosis. Undiﬀeren-
tiated endometrial sarcomas display morphologic diversity
w h i c hm a yb et h es o u r c eo fd i a g n o s t i cd i ﬃculties. Probably
the very ﬁrst case of poorly diﬀerentiated endometrial stro-
mal sarcoma with osteochondromatous diﬀerentiation and
benign appearing giant cells is documented approximately
30 years ago by Evans in 1982 [3] howeverthis neoplasm was
not described in detail. In 2005 Fadare et al. [4] described
a unique case of a low-grade endometrial stromal sarcoma
with smooth muscle diﬀerentiation which was associated
with the presence of osteoclast-like giant cells; however the
ﬁrst case oftrue giant cell “nonleiomyomatous” tumorofthe
uterus was described in 2007 by Skubitz and Carlos Manivel
[5]. The authors describe a case of a 55-year-old female
who was found to have a uterine neoplasm with multiple
lung nodules. The neoplasm was composed of atypical plum
mononuclear cell and numerous osteoclast-type giant cells.
The neoplastic mononuclear cells demonstrated positive
Vimentin, focal CD10 stains as well as week actin stains;
however,theytestednegativeforDesminandSmoothmuscle
myosin arguing against the smooth muscle origin of this
tumor. The authors classiﬁed this tumor as a giant cell
tumor of the uterus similar to the giant cell tumor of bone.
Although osteoclast-like giant cells have been described in2 Pathology Research International
a variety of other tumors including leiomyosarcoma of the
uterine corpus and giant cell tumor of tendon sheath, this
was the ﬁrst reported case describing osteoclast-like giant
cells in association with high-grade endometrial stromal
sarcoma.
In this paper we report and characterize a case of undif-
ferentiated endometrial sarcoma with osteoclast giant cells.
We also elaborate on the cytological, gross and microscopic
pathological ﬁndings, including the immunohistochemical
proﬁle of this unique entity.
2.Materialsand Methods
The specimen was ﬁxed in 10% formalin and processed for
histologic examination using conventional methods.
Immunohistochemical analysis was performed using
formalin-ﬁxed, paraﬃn-embedded sections. The avidin-
biotin peroxidase complex technique and the peroxidase-
antiperoxidase techniques were employed. Commercially
available antibodies used in this study are summarized in
Table 1. Appropriate positive and negative control experi-
ments were also performed.
3.Results
3.1. Report of Case. The patient is a 46-year-old female who
presented in Feb 2009 to the Long Island College Hospital
with menorrhagia, lower abdominal cramping, anemia and
vaginal bleeding. Sonogram was performed and demon-
strated a 13.5 × 10.1cm uterus with multiple ﬁbroids.
The patient underwent an endometrial biopsy which was
nondiagnostic and showed mostly blood and fragments of
unremarkable endocervical and squamous epithelium. The
recurrent vaginal bleeding prompted a private gynecologic
oﬃce visit for uterine artery embolization. Since the proce-
dure failed to stop the bleeding, she was readmitted to the
hospital in May 2009.AThinPrep Pap smear performed dur-
ing this admission showed evidenceof ahigh-grade sarcoma.
A subsequent endometrial biopsy conﬁrmed the cytological
diagnosis of high-grade sarcoma and also demonstrated
a presence of numerous osteoclast-like giant cells.
At the end of May 2009, the patient underwent a total
hysterectomy with bilateral salpingo-oophorectomy with
lymph node dissection. The surgery was uneventful.
3.2. Radiologic Findings. CT of the abdomen and pelvis was
performed from the dome of the diaphragm to the pubic
symphysis after administration of oral and IV contrast via
5mmreconstruction.
The gynecological structures demonstrated an enlarged
myomatous uterus with areas of low attenuation which were
interpreted as representing areas of necrosis. The estimated
anterior-posterior diameter dimension of this large hypo-
density was 10.8cm (Figure 1(a)). Subsequent MRI revealed
an intramural lesion with a large submucosal component
which distorted the underlying endometrium.
3.3. Cytology Findings. The ThinPrep Pap smear, obtained
prior to the endometrial biopsy, was paucicellular showing
predominantly blood and granular ﬁbrinous background.
The majority of the malignant cells were clustered at the
periphery of the slide leaving an empty central area. The
tumor cells, round to spindle, were intermediate in size,
with nuclei measuring approximately 15–25microns. The
cytoplasm was abundant and ﬁnely granular. The nuclei
were positioned eccentrically with coarse to “pitch dark”
chromatin and inconspicuous nucleoli. There was marked
nuclear atypia and variable anisocytosis with large, hyper-
chromatic nuclei and marked nuclear membrane irregular-
ities. Numerous abnormal mitotic ﬁgures were also found.
Individual cell apoptosis and cellular mummiﬁcation was
readily apparent and there was abundant ﬁnely granular
tumor diathesis (Figure 1(b)). Nuclear palisading, rosetting
or myxoid changes were not observed. Numerous osteoclast-
like giant cells were identiﬁed intimately mixed with the
tumor cells. These giant cells were found to have and abun-
dant cytoplasm with well-deﬁned cytoplasmic borders and
approximately 10–20 nuclei some of which show prominent
nucleoli (Figure 1(c)).
3.4. Gross Anatomic Findings. The specimen received for
pathologic evaluation consisted of an intact uterus and
weighing 530g with attached bilateral adnexa. The uterine
serosal surface was smooth with no obvious tumor implants
or perforation. Opening the endometrial cavity revealed
a1 2 .5×6.0×3.5cm necrotic polypoid tumor, occupying the
anterior and posterior endometrium. The lesion was limited
to the corpusand did not extend to the endocervix. It grossly
invaded more than onehalf ofthe myometrium approaching
theserosalsurface(Figure1(d)).Thecutsurfaceofthetumor
was yellow, ﬂeshy, centrally hemorrhagic and necrotic with
multiple ﬁbrotic/desmoplastic areas. The attached fallopian
tubes and ovaries did not show any evidence of tumor
involvement.
3.5. Light Microscopic Findings. The histologic sections
revealed a highly pleomorphic spindle cell neoplasm, inﬁl-
trating deep into the myometrium. A second population
of round and polygonal cells was also observed with high
mitotic index (50–100/10HPF), individual cell apoptosis
and necrosis (Figure 1(e)). This high-grade sarcoma also
showed rare extremely pleomorphic cells with abundant
deeply eosinophilic cytoplasm and hyperchromatic nuclei
with nuclearsizesexceeding 50microns(Figure1(f)).Alym-
phovascular invasion was also identiﬁed.
Additionally, numerous osteoclast-like giant cells were
observed, evenly distributed within the tumor. Similar to the
cytological ﬁnding on ThinPrep Pap smear they contained
numerous (10–20) bland nuclei, some of which showed
prominent nucleoli. These nuclei were partially overlapping
and clustered at the center of the cytoplasm.
The tumorwas notfound toextend intothe endocervical
stroma orglands and the regional lymph nodes did not show
evidence of metastatic disease. The peritoneal washings were
also negative.
Immunohistochemical analysis of the tumor revealed
strong positivity for CD10 and focal positivity for Inhibin
and WT-1. The tumor cells tested negative for Myoglobin,Pathology Research International 3
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Figure1:(a)MRI (T1weighted, after Gadoliniuminjection):Enlargeduterus withcentralhypodense area.(b)ThinPrepPapsmearshowing
numerous spindle cells with marked anysocytosis, anisonucleosis and chromatin condensation. The background shows granular tumor
diathesis and blood (Pap, 400x). (c) ThinPrep Pap smear: Multinucleated giant cells in association with single spindle and more epithelioid
appearing malignant cells (PAP, 400x). (d) Hysterectomy gross specimen showing anterior and posterior endometrial cavities occupied
with tumor with central hemorrhagic area. (e) Histologic sections showing high-grade sarcoma with osteoclast-like giant cells, numerous
mitoticﬁgures andindividual cell apoptosis(H&E, 200x).(f)Highpower view ofhistologicalsectionsshowingundiﬀerentiated endometrial
sarcoma with marked cellular pleomorphism and atypical mitoses (H&E, 400x).
Caldesmon, Desmin, Myogenin, AE1/3, S-100, Calretinin
and CD56. The multinucleated osteoclast-like giant cells
were found to be strongly positive for CD68 (Table 1).
Some of these cells (less than 2% of the total osteoclast-like
giant cell population) also exhibited a weak 2+ cytoplasmic
stain for b-HCG; however typical trophoblastic cells were
not identiﬁed. While this observation is of little clinical
signiﬁcance it is important not to misdiagnose this entity as
an epithelial tumor with trophoblastic giant cells especially
when dealing with limited material. The Estrogen and Pro-
gesterone receptors as well as CD117 (c-kit) were negative.
4.Discussion
Endometrial stromal tumors are rare mesenchymal neo-
plasms which occur in females between ages of 40 and
60 years often presenting with menometrorrhagia as most
common symptom [1, 6] .T h e s er a r en e o p l a s m sw e r e
described and characterized in 1966 by Norris and Taylor [7]
who classiﬁed them as benign stromal nodules or malignant
sarcomas, depending on the degree of the mitotic activity.
Currently, malignant stromal neoplasms are deﬁned by the
WHO as high-grade endometrial sarcomas thatlacksspeciﬁc
diﬀerentiation and bears no histologic resemblance to the
endometrial stroma [2].
Evans was the ﬁrst one to document the osteochondro-
matous diﬀerentiation in endometrial stromal sarcoma [3],
and additionally, in 2005, Fadare et al. [4] described a case
of a 70-year-old woman who underwent total abdominal
hysterectomy for recurrent polyps and an enlarging uterine
mass. The light microscopic evaluation showed that the
tumor was composed of short fusiform cells with minimal4 Pathology Research International
Table 1: Immunohistochemicalstains used in this study and tumor staining results.
Antibody Clone Source Dilution Company Staining results
Caldesmon h-CD Mouse 1:400 Dako Negative
Calretinin 5A5 Mouse RTU1 Novocastra Negative
CD10 56C6 Mouse RTU Leica Positive, 3+ in >95% cells
CD56 CD564 Mouse RTU Leica Negative
CD68 514H12 Mouse RTU Leica Positive in osteoclast-likegiant cells
AE1-3 AE1/AE3 Mouse 1:200 Covance Negative
DES D33 Mouse 1:1K Dako Negative
HCG Polyclonal Rabbit 1:2K Dako Rare giant cells were positive
INHIBIN-a R1 Mouse 1:5 Serotec Positive
Myf-4 LO26 Mouse 1:50 Novocastra Negaive
MYO Polyclonal Rabbit 1:2K Dako Negative
S-100 Polyclonal Rabbit RTU Leica Negative
WT-1 WT49 Mouse RTU Leica Positive, 40%–50% tumor cells
ER 1D5 Mouse 1:50 Dako Negative
PR Pgt636 Mouse 1:500 Dako Negative
CD117 Polyclonal Rabbit 1:400 Dako Negative
1RTU: Ready to use.
cytoplasm and a rich vascular network composed of small
capillaries. The tumor was also shown to have focal smooth
muscle diﬀerentiation and mitotic activity of 3–5/10HPF.
This low-grade endometrial stromal sarcoma was unique
because it was the ﬁrst endometrial stromal tumor that was
associated with the presence of osteoclast-like giant cells.
The osteoclast-like giant cells share a morphologic and
immunohistochemical similarities to regular osteoclast cells
[8] and have been described in association with a variety
of other tumors including poorly diﬀerentiated liver and
pancreatic carcinoma [8–11]. They are believed to be of
histiocytic origin, as proven by their immunophenotype and
ultrastructure [4, 8, 9]. The exact relationship between these
cells and the high-grade tumors is currently unknown. One
theory suggests that these cells could represent transformed
tumor cells. This theory was supported by molecular studies
of giant cell tumors of pancreas and liver showing the same
K-ras mutations in the tumor cells and their precursor
lesions[10].Alternativetheorywhich gainedmoresupportis
that these osteoclast-like giant cells are stromal in origin and
represent a reactive host response. The fact that these cells
were found to be diploid while the adjacent tumor cells were
found to be aneuploid or hyperploid [11] further supports
this theory.
In contrast to the low-grade endometrial sarcoma
described by Fadare et al., the case presented in this paper
is an aggressive sarcoma. Necrosis was readily appreciated,
the mitotic counts were high, 50–100/10HPF, and the tumor
inﬁltrated diﬀusely into the myometrium approaching the
serosal surface. The immunohistochemical analysis showed
that the tumor was positive for CD10 and negative for
smooth muscle markers.
CD10 is a surface neutral endopeptidase which was
described in immature lymphoid cells [12]a n dl a t e rw a s
found to be a sensitive diagnostic marker for a majority
of endometrial stromal sarcomas [13]. This marker is
also found to be expressed in high-grade lesions such as
leiomyosarcoma [14]; however, as previously mentioned
above,the present case tested negative for myogenic markers.
Kurihara et al. recommended a new terminology and
classiﬁcation of undiﬀerentiated endometrial sarcomas
(nonlow-grade endometrial stromal sarcomas) based on
nuclear pleomorphism [15]. They divided these sarcomas
in two groups: undiﬀerentiated endometrial sarcoma with
nuclear uniformity (UES-U) and undiﬀerentiated endome-
trial sarcoma with nuclear pleomorphism (UES-P). They
showed that UES-U shares some molecular and immunohis-
tochemical characteristics with low-grade endometrial sar-
coma while considerable diﬀerences were observed between
UES-P and low-grade tumors.
Based on the inﬁltrative growth pattern, increased mi-
totic ﬁgures, necrosis, and marked cellular atypia we have
classiﬁedthistumorasundiﬀerentiatedendometrialsarcoma
with osteoclast-like giant cells. Using the Kurihara classiﬁca-
tionthistumorshould be classiﬁed as type2 tumororundif-
ferentiatedendometrialsarcomawithnuclearpleomorphism
and osteoclast-like giant cells. The histological diﬀerential
diagnosis in such cases is broad and includes: endometrial
carcinosarcoma with osteoclast-like giant cells as described
by Amant et al. [16] (positivity of the epithelial components
for EMA and Pancytokeratin), undiﬀerentiated metastatic
carcinoma (AE1/3 positivity), primary uterine carcinomas,
epithelioid leiomyosarcoma (myogenic markers positivity)
or metastatic gastrointestinal stromal tumors [17, 18]
(CD117 positivity). Mixed Mullerian tumors were shown
to resemble endometrial stroma tumors with positivity
for CD10, WT-1, and pancytokeratin as well as variable
expressionofestrogen,progesterone,androgenreceptorsand
myogenicmarkers[19].Thecas ew epr es entinthispaperwas
extensively sampled and shown to be completely negative forPathology Research International 5
pancytokeratin(AE1/3),estrogenandprogesteronereceptors
as well as myogenic markers (desmin and myogenin) thus
ruling out the diagnosis of mixed Mullerian tumor with
stromal sarcomatous overgrowth, the negativity for myo-
genicmarkersalsorulesoutepithelioidleyomiosarcoma.The
negativity of CD117 (c-kit) also ruled out the possibility
of malignant gastrointestinal stromal tumor with osteoclast-
like giant cells [18].
Microscopically, the tumor was inﬁltrating more than
two thirds of the myometrium without detectable extension
into the endocervical stroma or endocervical glands. The
bilateral adnexa were free of tumor and the pelvic wash was
negative for malignancy. The tumor was staged as pT1b(Ib),
N0 and M0. Although the regional lymph nodes were
negative, extensive lymphovascular permeation was present.
The tumor disseminated to the peritoneal cavity and lungs
causing a vascular thrombosis which led to bowel ischemia
and subsequent peritonitis and sepsis.
To the best of our knowledge, this is the ﬁrst report
of a case showing an undiﬀerentiated endometrial sarcoma
with nuclear pleomorphism associated with presence of
osteoclast-like giant cells and no true osteochondromatous
diﬀerentiation, which further expands the spectrum of this
rare uterine neoplasms. We believe that the osteoclast-like
giant cells are most probably from stromal or peripheral
blood origin, attracted by the presence of speciﬁc cytokines
released by the tumor. Although the tumor was found to
have a low pathologic stage, it proved to be a neoplasm with
highly aggressive behavior and rapid progression. Perhaps
this morphologic variant signiﬁes a poor prognosis and
requires a more aggressive treatment plan.
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